Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Chimeric antigen receptor T cells for treatment of transformed Waldenström macroglobulinemia.

Bansal R, Jurcic JG, Sawas A, Mapara MY, Reshef R.

Leuk Lymphoma. 2019 Sep 22:1-4. doi: 10.1080/10428194.2019.1665668. [Epub ahead of print] No abstract available.

PMID:
31544563
2.

Targeted Alpha-Particle Therapy for Hematologic Malignancies.

Jurcic JG.

J Med Imaging Radiat Sci. 2019 Jun 25. pii: S1939-8654(19)30276-0. doi: 10.1016/j.jmir.2019.05.008. [Epub ahead of print]

PMID:
31253514
3.

Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies.

Jurcic JG.

Curr Radiopharm. 2018;11(3):192-199. doi: 10.2174/1874471011666180525102814. Review.

PMID:
29793418
4.

Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.

Maslak PG, Dao T, Bernal Y, Chanel SM, Zhang R, Frattini M, Rosenblat T, Jurcic JG, Brentjens RJ, Arcila ME, Rampal R, Park JH, Douer D, Katz L, Sarlis N, Tallman MS, Scheinberg DA.

Blood Adv. 2018 Feb 13;2(3):224-234. doi: 10.1182/bloodadvances.2017014175.

5.

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.

Komrokji R, Garcia-Manero G, Ades L, Prebet T, Steensma DP, Jurcic JG, Sekeres MA, Berdeja J, Savona MR, Beyne-Rauzy O, Stamatoullas A, DeZern AE, Delaunay J, Borthakur G, Rifkin R, Boyd TE, Laadem A, Vo B, Zhang J, Puccio-Pick M, Attie KM, Fenaux P, List AF.

Lancet Haematol. 2018 Feb;5(2):e63-e72. doi: 10.1016/S2352-3026(18)30002-4. Epub 2018 Jan 10.

PMID:
29331635
6.

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.

Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M.

Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20. Erratum in: Lancet Oncol. 2017 Dec;18(12 ):e711. Lancet Oncol. 2018 Jul;19(7):e335. Lancet Oncol. 2019 Jun;20(6):e293.

7.

Androgen Maintenance Therapy for Acute Myeloid Leukemia.

Jurcic JG.

J Clin Oncol. 2017 Feb;35(4):381-383. doi: 10.1200/JCO.2016.70.4999. Epub 2016 Nov 14. No abstract available.

PMID:
28129529
8.

Highlights in Hematologic Malignancy Treatments: Leukemia, Myelodysplastic Syndromes, and Allotransplant-New Drugs on the Horizon for Acute Myeloid Leukemia.

Jurcic JG.

JAMA Oncol. 2017 Mar 1;3(3):299-300. doi: 10.1001/jamaoncol.2016.3928. No abstract available.

PMID:
27787556
9.

Severe mechanical hemolysis in a patient with thalassemia minor who had undergone inappropriate splenectomy.

Falchi L, Grillo LM, Diuguid-Gerber JL, Eisenberger AB, Jurcic JG.

Int J Hematol. 2016 Aug;104(2):147-8. doi: 10.1007/s12185-016-2023-1. Epub 2016 May 20. No abstract available.

PMID:
27206816
10.

Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS).

Abel GA, Efficace F, Buckstein RJ, Tinsley S, Jurcic JG, Martins Y, Steensma DP, Watts CD, Raza A, Lee SJ, List AF, Klaassen RJ.

Haematologica. 2016 Jun;101(6):781-8. doi: 10.3324/haematol.2015.140335. Epub 2016 Mar 4.

11.

Targeted alpha-particle immunotherapy for acute myeloid leukemia.

Jurcic JG, Rosenblat TL.

Am Soc Clin Oncol Educ Book. 2014:e126-31. doi: 10.14694/EdBook_AM.2014.34.e126. Review.

12.

Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death.

Altman JK, Rademaker A, Cull E, Weitner BB, Ofran Y, Rosenblat TL, Haidau A, Park JH, Ram SL, Orsini JM Jr, Sandhu S, Catchatourian R, Trifilio SM, Adel NG, Frankfurt O, Stein EM, Mallios G, Deblasio T, Jurcic JG, Nimer S, Peterson LC, Kwaan HC, Rowe JM, Douer D, Tallman MS.

Leuk Res. 2013 Sep;37(9):1004-9. doi: 10.1016/j.leukres.2013.05.007. Epub 2013 Jun 14.

PMID:
23768930
13.

Radioimmunotherapy for hematopoietic cell transplantation.

Jurcic JG.

Immunotherapy. 2013 Apr;5(4):383-94. doi: 10.2217/imt.13.11. Review.

PMID:
23557421
14.

Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia.

Sekeres MA, Lancet JE, Wood BL, Grove LE, Sandalic L, Sievers EL, Jurcic JG.

Haematologica. 2013 Jan;98(1):119-28. doi: 10.3324/haematol.2012.066613. Epub 2012 Jul 16.

15.

What happened to anti-CD33 therapy for acute myeloid leukemia?

Jurcic JG.

Curr Hematol Malig Rep. 2012 Mar;7(1):65-73. doi: 10.1007/s11899-011-0103-0. Review.

PMID:
22109628
16.

Induction and postremission strategies in acute myeloid leukemia: state of the art and future directions.

Rosenblat TL, Jurcic JG.

Hematol Oncol Clin North Am. 2011 Dec;25(6):1189-213. doi: 10.1016/j.hoc.2011.09.007. Review.

PMID:
22093583
17.

Emerging new approaches for the treatment of acute promyelocytic leukemia.

Park J, Jurcic JG, Rosenblat T, Tallman MS.

Ther Adv Hematol. 2011 Oct;2(5):335-52. doi: 10.1177/2040620711410773.

18.

Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid.

Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL, Altman JK, Douer D, Rowe JM, Tallman MS.

Blood. 2011 Aug 4;118(5):1248-54. doi: 10.1182/blood-2011-04-346437. Epub 2011 Jun 8.

19.

Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia.

Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, Heaney ML, Chanel S, Morgenstern A, Sgouros G, Larson SM, Scheinberg DA, Jurcic JG.

Clin Cancer Res. 2010 Nov 1;16(21):5303-11. doi: 10.1158/1078-0432.CCR-10-0382. Epub 2010 Sep 21.

20.

Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial.

Raza A, Jurcic JG, Roboz GJ, Maris M, Stephenson JJ, Wood BL, Feldman EJ, Galili N, Grove LE, Drachman JG, Sievers EL.

Leuk Lymphoma. 2009 Aug;50(8):1336-44. doi: 10.1080/10428190903050013.

PMID:
19557623
21.

Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.

Lamanna N, Jurcic JG, Noy A, Maslak P, Gencarelli AN, Panageas KS, Heaney ML, Brentjens RJ, Golde DW, Scheinberg DA, Zelenetz AD, Weiss MA.

J Clin Oncol. 2009 Feb 1;27(4):491-7. doi: 10.1200/JCO.2008.16.4459. Epub 2008 Dec 15.

22.

Ab therapy of AML: native anti-CD33 Ab and drug conjugates.

Jurcic JG.

Cytotherapy. 2008;10(1):7-12. Review.

PMID:
17917880
23.

Diagnosis and treatment of acute promyelocytic leukemia.

Jurcic JG, Soignet SL, Maslak AP.

Curr Oncol Rep. 2007 Sep;9(5):337-44. Review.

PMID:
17706161
24.

Monoclonal antibody therapy of APL.

Maslak PG, Jurcic JG, Scheinberg DA.

Curr Top Microbiol Immunol. 2007;313:205-19. Review.

PMID:
17217045
25.

Antibody-drug conjugates in acute myeloid leukemia.

Scheinberg DA, Jurcic JG, Maslak P.

Nat Clin Pract Oncol. 2006 May;3(5):238-9. No abstract available.

PMID:
16682998
26.

Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.

Lamanna N, Kalaycio M, Maslak P, Jurcic JG, Heaney M, Brentjens R, Zelenetz AD, Horgan D, Gencarelli A, Panageas KS, Scheinberg DA, Weiss MA.

J Clin Oncol. 2006 Apr 1;24(10):1575-81. Epub 2006 Mar 6.

PMID:
16520464
27.

Immunotherapy for acute myeloid leukemia.

Jurcic JG.

Curr Oncol Rep. 2005 Sep;7(5):339-46. Review.

PMID:
16091194
28.

The promise of targeted {alpha}-particle therapy.

Mulford DA, Scheinberg DA, Jurcic JG.

J Nucl Med. 2005 Jan;46 Suppl 1:199S-204S. Review.

29.

Radioimmunotherapy of leukemia.

Burke JM, Jurcic JG.

Adv Pharmacol. 2004;51:185-208. Review. No abstract available.

PMID:
15464910
30.

Antibody-based treatment of acute myeloid leukaemia.

Mulford DA, Jurcic JG.

Expert Opin Biol Ther. 2004 Jan;4(1):95-105. Review.

PMID:
14680472
31.

Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.

Burke JM, Caron PC, Papadopoulos EB, Divgi CR, Sgouros G, Panageas KS, Finn RD, Larson SM, O'Reilly RJ, Scheinberg DA, Jurcic JG.

Bone Marrow Transplant. 2003 Sep;32(6):549-56.

PMID:
12953125
32.

Monitoring PML-RARalpha in acute promyelocytic leukemia.

Jurcic JG.

Curr Oncol Rep. 2003 Sep;5(5):391-8. Review.

PMID:
12895391
33.

Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.

Weiss MA, Maslak PG, Jurcic JG, Scheinberg DA, Aliff TB, Lamanna N, Frankel SR, Kossman SE, Horgan D.

J Clin Oncol. 2003 Apr 1;21(7):1278-84.

PMID:
12663715
34.

Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin.

Aliff TB, Maslak PG, Jurcic JG, Heaney ML, Cathcart KN, Sepkowitz KA, Weiss MA.

Cancer. 2003 Feb 15;97(4):1025-32.

35.

A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia.

Weiss MA, Aliff TB, Tallman MS, Frankel SR, Kalaycio ME, Maslak PG, Jurcic JG, Scheinberg DA, Roma TE.

Cancer. 2002 Aug 1;95(3):581-7.

36.

Targeted alpha particle immunotherapy for myeloid leukemia.

Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangrud AM, Hamacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R, Scheinberg DA.

Blood. 2002 Aug 15;100(4):1233-9.

PMID:
12149203
37.

Antibody therapy in acute myeloid leukemia: current status and future directions.

Burke JM, Jurcic JG.

Clin Lymphoma. 2002 Mar;2 Suppl 1:S12-8. Review.

PMID:
11970765
38.

Radioimmunotherapy for acute leukemia.

Burke JM, Jurcic JG, Scheinberg DA.

Cancer Control. 2002 Mar-Apr;9(2):106-13. Review.

PMID:
11965231
39.

Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia.

Jurcic JG, Nimer SD, Scheinberg DA, DeBlasio T, Warrell RP Jr, Miller WH Jr.

Blood. 2001 Nov 1;98(9):2651-6.

PMID:
11675334
40.

Novel therapeutics for chemotherapy-resistant acute myeloid leukaemia.

Frankel AE, Schuster MW, Jurcic JG.

BioDrugs. 2001;15(1):55-71. Review.

PMID:
11437675
41.

Acute myeloid leukemia with t(5;18)(q35;q21).

Wang ES, Maslak P, Cathcart K, Jurcic JG.

Cancer Genet Cytogenet. 2001 May;127(1):71-3.

PMID:
11408069
42.

Antibody therapy for residual disease in acute myelogenous leukemia.

Jurcic JG.

Crit Rev Oncol Hematol. 2001 Apr;38(1):37-45. Review.

PMID:
11255080
43.

Parametric images of antibody pharmacokinetics in Bi213-HuM195 therapy of leukemia.

Kolbert KS, Hamacher KA, Jurcic JG, Scheinberg DA, Larson SM, Sgouros G.

J Nucl Med. 2001 Jan;42(1):27-32.

44.

Antibody immunotherapy for leukemia.

Jurcic JG.

Curr Oncol Rep. 2000 Mar;2(2):114-22. Review.

PMID:
11122832
45.

Antibody therapy of acute myelogenous leukemia.

Jurcic JG.

Cancer Biother Radiopharm. 2000 Aug;15(4):319-26. Review.

PMID:
11041016
46.

Advances in immunotherapy of hematologic malignancies: cellular and humoral approaches.

Jurcic JG, Cathcart K, Pinilla-Ibarz J, Scheinberg DA.

Curr Opin Hematol. 2000 Jul;7(4):247-54. Review.

PMID:
10882181
47.

Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia.

Jurcic JG, DeBlasio T, Dumont L, Yao TJ, Scheinberg DA.

Clin Cancer Res. 2000 Feb;6(2):372-80.

48.

Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia.

Sgouros G, Ballangrud AM, Jurcic JG, McDevitt MR, Humm JL, Erdi YE, Mehta BM, Finn RD, Larson SM, Scheinberg DA.

J Nucl Med. 1999 Nov;40(11):1935-46.

49.

Radionuclides as conditioning before stem cell transplantation.

Jurcic JG, Scheinberg DA.

Curr Opin Hematol. 1999 Nov;6(6):371-6. Review.

PMID:
10546789
50.

A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.

Kossman SE, Scheinberg DA, Jurcic JG, Jimenez J, Caron PC.

Clin Cancer Res. 1999 Oct;5(10):2748-55.

Supplemental Content

Loading ...
Support Center